Q-omics provides the consensus-scored PDE4DIPP3 profile across patient tissues and cancer cell-line models. PDE4DIPP3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDE4DIPP3 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, PDE4DIPP3 RNA expression shows 6,687 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BRCA, and STAD as cancer lineages where PDE4DIPP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4DIPP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4DIPP3 survival associations across molecular data types. PDE4DIPP3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4DIPP3 RNA expression–survival associations across cancer types. High PDE4DIPP3 expression shows unfavorable associations in UVM, COAD, KICH, STAD, ESCA and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDE4DIPP3 RNA expression.
This table summarizes PDE4DIPP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PDE4DIPP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4DIPP3 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BRCA, KIRP and KIRC. The BRCA box plot shows higher PDE4DIPP3 RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p < 0.001).
This table shows molecular features associated with PDE4DIPP3 in patient tissues and cancer cell lines. In patient samples, PDE4DIPP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
